The latest price target for Nautilus Biotechnology (NASDAQ:NAUT) was reported by Goldman Sachs on December 5, 2024. The analyst firm set a price target for $1.75 expecting NAUT to fall to within 12 months (a possible -1.13% downside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Nautilus Biotechnology (NASDAQ:NAUT) was provided by Goldman Sachs, and Nautilus Biotechnology downgraded their sell rating.

There is no last upgrade for Nautilus Biotechnology

The last downgrade for Nautilus Biotechnology Inc happened on December 5, 2024 when Goldman Sachs changed their price target from $2.25 to $1.75 for Nautilus Biotechnology Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Nautilus Biotechnology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Nautilus Biotechnology was filed on December 5, 2024 so you should expect the next rating to be made available sometime around December 5, 2025.

While ratings are subjective and will change, the latest Nautilus Biotechnology (NAUT) rating was a downgraded with a price target of $2.25 to $1.75. The current price Nautilus Biotechnology (NAUT) is trading at is $1.77, which is out of the analyst’s predicted range.